Display options
Cite
Stuchlik A, Radostová D, Hatalova H, et al. Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies. Front Behav Neurosci. 2016;10:209doi: 10.3389/fnbeh.2016.00209.
Stuchlik, A., Radostová, D., Hatalova, H., Vales, K., Nekovarova, T., Koprivova, J., Svoboda, J., & Horacek, J. (2016). Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies. Frontiers in behavioral neuroscience, 10209. https://doi.org/10.3389/fnbeh.2016.00209
Stuchlik, Ales, et al. "Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies." Frontiers in behavioral neuroscience vol. 10 (2016): 209. doi: https://doi.org/10.3389/fnbeh.2016.00209
Stuchlik A, Radostová D, Hatalova H, Vales K, Nekovarova T, Koprivova J, Svoboda J, Horacek J. Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies. Front Behav Neurosci. 2016 Oct 26;10:209. doi: 10.3389/fnbeh.2016.00209. eCollection 2016. PMID: 27833539; PMCID: PMC5080285.
Copy Download .nbib Format: NLM
Share it on

Front Behav Neurosci. 2016 Oct 26;10:209. doi: 10.3389/fnbeh.2016.00209. eCollection 2016.

Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies.

Frontiers in behavioral neuroscience

Ales Stuchlik, Dominika Radostová, Hana Hatalova, Karel Vales, Tereza Nekovarova, Jana Koprivova, Jan Svoboda, Jiri Horacek

Affiliations

  1. Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of Sciences Prague, Czech Republic.
  2. Department of Neurophysiology of Memory, Institute of Physiology, Czech Academy of SciencesPrague, Czech Republic; National Institute of Mental HealthKlecany, Czech Republic.
  3. National Institute of Mental Health Klecany, Czech Republic.

PMID: 27833539 PMCID: PMC5080285 DOI: 10.3389/fnbeh.2016.00209

Abstract

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder with 1-3% prevalence. OCD is characterized by recurrent thoughts (obsessions) and repetitive behaviors (compulsions). The pathophysiology of OCD remains unclear, stressing the importance of pre-clinical studies. The aim of this article is to critically review a proposed animal model of OCD that is characterized by the induction of compulsive checking and behavioral sensitization to the D2/D3 dopamine agonist quinpirole. Changes in this model have been reported at the level of brain structures, neurotransmitter systems and other neurophysiological aspects. In this review, we consider these alterations in relation to the clinical manifestations in OCD, with the aim to discuss and evaluate axes of validity of this model. Our analysis shows that some axes of validity of quinpirole sensitization model (QSM) are strongly supported by clinical findings, such as behavioral phenomenology or roles of brain structures. Evidence on predictive validity is contradictory and ambiguous. It is concluded that this model is useful in the context of searching for the underlying pathophysiological basis of the disorder because of the relatively strong biological similarities with OCD.

Keywords: OCD; animal model; brain circuits; human; quinpirole; rat

References

  1. Brain Res. 2003 Feb 28;964(2):295-301 - PubMed
  2. Eur J Pharmacol. 1997 Mar 19;322(2-3):123-7 - PubMed
  3. Pharmacol Biochem Behav. 1991 Oct;40(2):311-5 - PubMed
  4. J Behav Addict. 2015 Dec;4(4):263-72 - PubMed
  5. Behav Brain Res. 1989 Sep 1;34(3):199-211 - PubMed
  6. J Neurochem. 2015 Sep;134(6):1081-90 - PubMed
  7. Neurosci Biobehav Rev. 2008;32(3):525-49 - PubMed
  8. Int J Neuropsychopharmacol. 2003 Dec;6(4):397-401 - PubMed
  9. Trends Cogn Sci. 2012 Jan;16(1):43-51 - PubMed
  10. J Psychiatry Neurosci. 2008 Sep;33(5):405-12 - PubMed
  11. J Clin Psychiatry. 2006 Jan;67(1):15-22 - PubMed
  12. BMC Psychiatry. 2014 Aug 02;14:214 - PubMed
  13. Neurosci Biobehav Rev. 2005 May;29(3):399-419 - PubMed
  14. Psychopharmacology (Berl). 2011 Dec;218(4):749-59 - PubMed
  15. Front Integr Neurosci. 2012 Jun 14;6:29 - PubMed
  16. Behav Brain Res. 2000 Apr;109(1):9-18 - PubMed
  17. Exp Neurol. 2008 Mar;210(1):217-28 - PubMed
  18. Br J Psychiatry Suppl. 1998;(35):26-37 - PubMed
  19. J Psychopharmacol. 2011 Dec;25(12):1712-9 - PubMed
  20. Arch Gen Psychiatry. 1989 Dec;46(12):1088-92 - PubMed
  21. Psychol Rev. 2004 Jan;111(1):111-27 - PubMed
  22. Biol Mood Anxiety Disord. 2011 Nov 07;1(1):9 - PubMed
  23. Neuropsychobiology. 2013;67(4):210-23 - PubMed
  24. J Exp Psychol. 1963 May;65:451-4 - PubMed
  25. Behav Pharmacol. 2008 Jul;19(4):271-83 - PubMed
  26. Dev Psychobiol. 1988 Nov;21(7):679-710 - PubMed
  27. Indian J Psychiatry. 2009 Jul-Sep;51(3):216-21 - PubMed
  28. Clin Neurophysiol. 2011 Jan;122(1):107-13 - PubMed
  29. Physiol Behav. 1995 Jan;57(1):55-9 - PubMed
  30. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1195-9 - PubMed
  31. Behav Brain Res. 2011 May 16;219(1):149-58 - PubMed
  32. Neurosci Biobehav Rev. 2013 Mar;37(3):328-39 - PubMed
  33. Psychopharmacology (Berl). 1994 Jun;115(1-2):95-104 - PubMed
  34. Eur J Neurosci. 2010 Nov;32(9):1552-63 - PubMed
  35. Arch Gen Psychiatry. 1999 Feb;56(2):121-7 - PubMed
  36. Psychiatry Res. 2009 Nov 30;170(1):15-21 - PubMed
  37. Depress Anxiety. 1998;8 Suppl 1:105-13 - PubMed
  38. Psychopharmacology (Berl). 2013 May;227(1):55-66 - PubMed
  39. Psychiatry Res. 2015 May 30;227(1):114-25 - PubMed
  40. Arch Gen Psychiatry. 1994 Apr;51(4):302-8 - PubMed
  41. Science. 2013 Jun 7;340(6137):1234-9 - PubMed
  42. Psychiatr Clin North Am. 1992 Dec;15(4):921-38 - PubMed
  43. Behav Brain Res. 2007 Feb 27;177(2):340-6 - PubMed
  44. Nat Neurosci. 2013 Apr;16(4):386-7 - PubMed
  45. Int J Neuropsychopharmacol. 2002 Jun;5(2):181-91 - PubMed
  46. Am J Psychiatry. 2006 Jul;163(7):1282-4 - PubMed
  47. Behav Pharmacol. 2015 Feb;26(1-2):200-16 - PubMed
  48. Neurosci Biobehav Rev. 2006;30(4):456-71 - PubMed
  49. Twin Res Hum Genet. 2005 Oct;8(5):450-8 - PubMed
  50. Pharmacol Biochem Behav. 2012 Feb;100(4):736-51 - PubMed
  51. Neurosci Lett. 2013 Aug 26;548:185-9 - PubMed
  52. Neuroscience. 2012 Jun 1;211:83-106 - PubMed
  53. Eur J Pharmacol. 2008 Sep 11;592(1-3):67-72 - PubMed
  54. Eur J Pharmacol. 1989 Feb 28;161(2-3):151-7 - PubMed
  55. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(6):677-90 - PubMed
  56. Int J Neuropsychopharmacol. 2013 Jun;16(5):1083-91 - PubMed
  57. Psychopharmacology (Berl). 2008 Oct;200(2):157-65 - PubMed
  58. Behav Neurosci. 1998 Dec;112(6):1475-85 - PubMed
  59. Behav Brain Res. 2017 Jan 15;317:210-217 - PubMed
  60. Arch Gen Psychiatry. 1998 Oct;55(10):918-24 - PubMed
  61. Eur J Neurosci. 2009 Jun;29(12):2401-12 - PubMed
  62. Biol Psychiatry. 2002 Jan 15;51(2):164-71 - PubMed
  63. Neurosci Biobehav Rev. 2016 May 7;:null - PubMed
  64. Behav Brain Res. 2012 Jun 1;231(2):289-96 - PubMed
  65. Front Behav Neurosci. 2014 Apr 11;8:122 - PubMed
  66. Lancet. 2002 Aug 3;360(9330):397-405 - PubMed
  67. Addict Health. 2015 Winter-Spring;7(1-2):37-46 - PubMed
  68. Rev Invest Clin. 2003 Nov-Dec;55(6):650-4 - PubMed
  69. BMC Neurosci. 2001;2:4 - PubMed
  70. Annu Rev Neurosci. 1986;9:357-81 - PubMed
  71. Trends Neurosci. 1990 Jul;13(7):266-71 - PubMed
  72. Neuropsychologia. 2009 Aug;47(10):2145-8 - PubMed
  73. Curr Opin Psychiatry. 2006 Jan;19(1):84-9 - PubMed
  74. Eur J Neurol. 2012 Jan;19(1):155-62 - PubMed
  75. Clin Neurophysiol. 2011 Sep;122(9):1735-43 - PubMed
  76. Neuropsychiatr Dis Treat. 2015 Aug 04;11:1939-55 - PubMed

Publication Types